NASDAQ:LVTX LAVA Therapeutics (LVTX) Stock Price, News & Analysis $1.60 -0.04 (-2.44%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.53▼$1.6450-Day Range$1.57▼$2.2952-Week Range$1.13▼$6.47Volume23,190 shsAverage Volume710,814 shsMarket Capitalization$40.56 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get LAVA Therapeutics alerts: Email Address LAVA Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside275.0% Upside$6.00 Price TargetShort InterestHealthy0.41% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.28) to ($1.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.96 out of 5 starsMedical Sector782nd out of 910 stocksPharmaceutical Preparations Industry365th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingLAVA Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLAVA Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about LAVA Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.41% of the float of LAVA Therapeutics has been sold short.Short Interest Ratio / Days to CoverLAVA Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LAVA Therapeutics has recently increased by 36.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLAVA Therapeutics does not currently pay a dividend.Dividend GrowthLAVA Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LVTX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for LAVA Therapeutics this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LAVA Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.79% of the stock of LAVA Therapeutics is held by insiders.Read more about LAVA Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for LAVA Therapeutics are expected to decrease in the coming year, from ($1.28) to ($1.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LAVA Therapeutics is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LAVA Therapeutics is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLAVA Therapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about LAVA Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary About LAVA Therapeutics Stock (NASDAQ:LVTX)LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.Read More LVTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LVTX Stock News HeadlinesSeptember 3, 2024 | globenewswire.comLAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 22, 2024 | markets.businessinsider.comLAVA Therapeutics: Promising Clinical Trials and Strategic Partnerships Bolster Buy RatingSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…August 21, 2024 | markets.businessinsider.comBuy Rating Affirmed: LAVA Therapeutics’ Financial Stability and Promising Clinical PipelineAugust 20, 2024 | globenewswire.comLAVA Reports Second Quarter 2024 Financial Results and Business UpdateAugust 8, 2024 | 247wallst.com4 Stocks Under $5 To Buy NowJune 20, 2024 | globenewswire.comLAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceJune 10, 2024 | globenewswire.comLAVA Announces Annual Meeting of ShareholdersSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…May 30, 2024 | globenewswire.comLAVA Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 21, 2024 | seekingalpha.comLAVA Therapeutics GAAP EPS of -$0.02 beats by $0.20, revenue of $6.99M beats by $3.49MMay 21, 2024 | globenewswire.comLAVA Provides Business Updates and Reports First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comLAVA Therapeutics to Participate in the Citizens JMP Life Sciences ConferenceMarch 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for LAVA Therapeutics Amid Promising T-Cell Cancer Therapy Trials and Strong FinancialsMarch 20, 2024 | finance.yahoo.comLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial ResultsMarch 20, 2024 | globenewswire.comLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial ResultsMarch 6, 2024 | finanznachrichten.deLAVA Therapeutics N.V.: LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)March 5, 2024 | msn.comLava gets $7M from Pfizer as trial for cancer drug advancesSee More Headlines Receive LVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/20/2024Today9/07/2024Next Earnings (Estimated)11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LVTX CUSIPN/A CIK1840748 Webwww.lavatherapeutics.com Phone31-85-016-3100FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+275.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,970,000.00 Net Margins-228.02% Pretax Margin-323.30% Return on Equity-48.53% Return on Assets-23.94% Debt Debt-to-Equity Ratio0.01 Current Ratio6.39 Quick Ratio6.39 Sales & Book Value Annual Sales$7.40 million Price / Sales5.48 Cash FlowN/A Price / Cash FlowN/A Book Value$3.39 per share Price / Book0.47Miscellaneous Outstanding Shares25,350,000Free FloatN/AMarket Cap$40.56 million OptionableOptionable Beta0.51 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Stephen Allen Hurly M.B.A. (Age 56)M.Sc., CEO, President & Executive Director Mr. Fred M. Powell CPA (Age 63)Chief Financial Officer Dr. Hans van der Vliet M.D. (Age 50)Ph.D., Chief Scientific Officer Ms. Amy Garabedian J.D. (Age 48)General Counsel & Corporate Secretary Mr. Wouter van HunnikVP & Head of Human ResourcesDr. Ton Adang Ph.D. (Age 63)Chief Development Officer Dr. Charles Q. Morris M.D. (Age 59)MBChB, MRCP (UK), Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsAdicet BioNASDAQ:ACETMediWoundNASDAQ:MDWDProQR TherapeuticsNASDAQ:PRQRCoherus BioSciencesNASDAQ:CHRSGalectin TherapeuticsNASDAQ:GALTView All CompetitorsInstitutional OwnershipXTX Topco LtdBought 30,807 shares on 8/12/2024Ownership: 0.122%Pathway Financial Advisors LLCBought 46,000 shares on 7/24/2024Ownership: 0.000%View All Institutional Transactions LVTX Stock Analysis - Frequently Asked Questions How have LVTX shares performed this year? LAVA Therapeutics' stock was trading at $1.58 at the start of the year. Since then, LVTX stock has increased by 1.3% and is now trading at $1.60. View the best growth stocks for 2024 here. How were LAVA Therapeutics' earnings last quarter? LAVA Therapeutics (NASDAQ:LVTX) released its quarterly earnings results on Tuesday, August, 20th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.05. LAVA Therapeutics had a negative trailing twelve-month return on equity of 48.53% and a negative net margin of 228.02%. When did LAVA Therapeutics IPO? LAVA Therapeutics (LVTX) raised $100 million in an initial public offering (IPO) on Thursday, March 25th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and SVB Leerink served as the underwriters for the IPO and Kempen & Co. was co-manager. Who are LAVA Therapeutics' major shareholders? Top institutional shareholders of LAVA Therapeutics include Pathway Financial Advisors LLC and XTX Topco Ltd (0.12%). How do I buy shares of LAVA Therapeutics? Shares of LVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LVTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.